Xeureka Inc. is a technology company focused on computational chemistry and small‑molecule drug discovery. It develops and applies advanced modeling and simulation approaches to support the design and optimization of candidate compounds.
The company works with industry partners to integrate in silico methods into discovery workflows, offering research collaborations and services that span virtual screening, structure‑based design, and lead optimization. Operating at the interface of chemistry, biology, and high‑performance computing, Xeureka aims to help accelerate R&D programs and improve decision‑making in early‑stage development across the pharmaceutical and related chemical sectors.
The collaboration uses advanced computational methods to discover new small-molecule cancer drugs, with Xeureka receiving upfront and milestone payments.
